The Lancet Respiratory Medicine considers any original research contribution that advocates change in or illuminates clinical practice and informative reviews on any topic connected with respiratory medicine and critical care.
The early use of azithromycin does not prevent the development of chronic lung disease in premature babies, finds new research by Cardiff University.
Apr 26, 2024
0
47
A major clinical trial, led by experts at the University of Nottingham, has shown that people with inflammatory conditions are able to improve the antibody response from a COVID-19 booster vaccination by interrupting their ...
Dec 12, 2023
0
31
A third of people hospitalized with COVID-19 have "abnormalities" in multiple organs months after getting infected, a UK study said on Saturday, potentially shedding light on the elusive condition of long COVID.
Sep 23, 2023
0
106
A major UK study has discovered that the disturbed sleep patterns in patients hospitalized with COVID-19 was likely to be a driver of breathlessness.
Apr 15, 2023
0
90
Researchers at the University of Nottingham have helped to develop a new tool called "CanPredict," which is able to identify the people most at risk of developing lung cancer over the next 10 years, and put them forward for ...
Apr 6, 2023
0
44
A new international study led by RCSI University of Medicine and Health Sciences has revealed significant potential for digital technology to improve asthma control for patients.
Apr 6, 2023
0
57
Remdesivir was one of the first medications approved for treatment of COVID-19. Clinical studies evaluated its effectiveness, but did not generate conclusive results. A new analysis of the study data shows that a specific ...
Feb 22, 2023
1
24
In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster ...
Dec 28, 2022
0
108
More than 15% of all critically ill patients who end up in intensive care with severe influenza or COVID-19 additionally develop aspergillosis, a pulmonary fungal infection. This doubles their mortality rate. A UZ Leuven ...
Aug 25, 2022
0
74
A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.
Jul 11, 2022
0
139
